Monopar Therapeutics MNPR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$13.72M+12.0% | -$15.59M-85.5% | -$8.4M+20.1% | -$10.52M-15.5% | ||
| $4.84M+324% | $1.14M-39.9% | $1.9M+15.6% | $1.64M— | ||
| —— | $506.79K+138% | -$1.33M— | —— | ||
| -$15.4K-221% | $12.78K— | —— | -$171.76K-99.3% | ||
| -$12.2M-90.5% | -$6.4M+18.5% | -$7.86M-8.7% | -$7.23M+1.2% | ||
| $87.15M+469% | $15.32M+94.2% | $7.89M— | —— | ||
| $23.7M+2,304% | $985.73K-92.3% | $12.81M— | $0— | ||
| -$63.45M-343% | -$14.34M-390% | $4.94M+200% | -$4.92M— | ||
| $0— | —— | $2.07M+1,797% | $109.34K— | ||
| $1.13M+986% | $104.22K+122% | $46.97K— | —— | ||
| $91.96M— | —— | $2.03M+6,067% | $32.87K— | ||
| $97.27K— | —— | —— | —— | ||
| —— | $38.55M— | —— | -$12.12M— | ||
| —— | $9.02K— | —— | —— | ||
| -$15.4K-221% | $12.78K— | —— | -$171.76K-99.3% | ||
| $0-100% | $4.55M— | $0— | —— | ||
| $87.15M+469% | $15.32M+94.2% | $7.89M— | —— | ||
| $23.7M+2,304% | $985.73K-92.3% | $12.81M— | $0— | ||
| $97.27K— | —— | —— | —— | ||
| —— | -$3M— | $0— | —— | ||
| $9.43K— | —— | $0— | —— | ||
| $291.43K— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monopar Therapeutics generate?
- Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
- Where does Monopar Therapeutics's cash flow data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.